1. Home
  2. RNAZ vs MNDO Comparison

RNAZ vs MNDO Comparison

Compare RNAZ & MNDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TransCode Therapeutics Inc.

RNAZ

TransCode Therapeutics Inc.

SELL

Current Price

$1.40

Market Cap

27.9M

Sector

Health Care

ML Signal

SELL

Logo MIND C.T.I. Ltd.

MNDO

MIND C.T.I. Ltd.

SELL

Current Price

$1.25

Market Cap

24.8M

Sector

Technology

ML Signal

SELL

Company Overview

Basic Information
Metric
RNAZ
MNDO
Founded
2016
1995
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
27.9M
24.8M
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
RNAZ
MNDO
Price
$1.40
$1.25
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
17.7K
★ 241.6K
Earning Date
08-14-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$8.57
Revenue Growth
N/A
N/A
52 Week Low
$1.30
$0.85
52 Week High
$12.60
$1.29

Technical Indicators

Market Signals
Indicator
RNAZ
MNDO
Relative Strength Index (RSI) 31.10 78.12
Support Level N/A $0.89
Resistance Level $1.93 $1.29
Average True Range (ATR) 0.15 0.02
MACD -0.02 0.05
Stochastic Oscillator 0.00 95.17

Price Performance

Historical Comparison
RNAZ
MNDO

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

About MNDO MIND C.T.I. Ltd.

MIND C.T.I. Ltd develops, manufactures, markets, and implements real-time and off-line convergent billing and customer care software solutions. It derives revenue from the sale of software products and services in two reportable segments, namely Billing and Related Services, which derives key revenue, and Messaging. The company has three product lines: Product Line A- billing and customer care solutions for service providers; Product Line B - call accounting and call management solutions for enterprises; and Product Line C - mobile messaging, communication, and payment solutions. Geographically, the company operates in the Americas, Europe, Asia Pacific and Africa, and Israel. It earns maximum revenue from Europe.

Share on Social Networks: